<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Cited in Smith & Nephew Meniscal Repair Press Release

Posted by Kristina Meyer on 12/20/18 9:30 AM

SmartTRAK was cited as a source in a press release from Smith & Nephew entitled "Smith & Nephew expands opportunity in meniscal repair through acquisition of unique and highly complementary technology."

Read More

Topics: Orthopedics-OrthoBio

SmartTRAK Interviews Cerapedics:  i-FACTOR, a Novel Bone Graft

Posted by Kim French on 8/15/18 10:07 AM

Cerapedics’ CEO Glen Kashuba and President and COO Jeff Marx, Ph.D. discuss the future of the bone graft substitutes and the uniqueness of i‑FACTOR Peptide Enhanced Bone Graft, a small peptide technology in an interview with Kim French, Sr. Analyst, SmartTRAK Orthbio.

A transcript of SmartTRAK's interview with Glen Kashuba and Jeff Marx is below, or click on the following video to listen to the interview.

Read More

Topics: Orthopedics-OrthoBio, SmartTRAK Interviews

SmartTRAK Publication Alert: Q118 OrthoBio Market Recap

Posted by Kim French on 6/19/18 12:54 PM

SmartTRAK, the leading source of competitive life sciences intelligence used by the top ten global orthopedic & wound care companies, has published its Q118 OrthoBio Market Recap.

Up 3.4% YoY, the OrthoBio market is off to a good start. Companies that are surpassing growth expectations tend to have differentiated products, focused efforts and incremental pull through from synergistic sales strategies. Market subtleties like reimbursement, pricing pressures and market loss due to newer competition continue to afflict some companies and segments...

Among the many topics covered in the full Q118 OrthoBio Market Recap are: 

Read More

Topics: Orthopedics-OrthoBio

SmartTRAK Publication Alert: Q317 OrthoBio Quarterly Market Recap

Posted by Kim French on 12/19/17 1:02 PM

Q317 OrthoBio Market: Hurricane related disruptions

Hurricane related disruptions, competition and sales force dynamics impacts third quarter results

By Kim French, Senior Analyst, SmartTRAK OrthoBio

For Q317, the US OrthoBio Market grew substantially, compared to Q316. Both positive and negative developments are impacting company results. Positive happenings include increased revenue generation from synergistic sales strategies, market share capture and expansion of new users or new products. Companies experiencing lower than expected performance report hurricane related disruptions, slow ramp-up of sales force expansion, product portfolio gaps and market share loss due to increased competition.

Read More

Topics: Orthopedics-OrthoBio

DKOU Spotlight: AgNovos Healthcare: Minimally Invasive Injectable Technique for Stabilizing Osteoporotic Hips

Posted by Sharon O'Reilly on 11/28/17 3:58 PM

SmartTRAK's President & CEO Sharon O'Reilly attended DKOU2017, the German Congress of Orthopedic and Trauma Surgery, in Berlin Oct. 24-27, 2017 and uncovered several new and innovative orthopedic, trauma and spine technologies on the exhibit floor.

This week, the SmartTRAK blog is featuring video interviews from DKOU highlighting new companies and products emerging from Europe.

Next up ...

Leanna Caron, EVP & CCO and Dr. James Howe, Founder & CMO - AgNovos Healthcare: A minimally invasive injectable technique for stabilizing osteoporotic hips 

Read More

Topics: Orthopedics-OrthoBio, Orthopedics-Trauma, SmartTRAK Conferences

Vivorté Cites BioMedGPS in the FORTERA and REGENTO bone grafting solutions Release

Posted by Sharon O'Reilly on 10/20/17 9:01 AM

Vivorté, Inc., a vertically-integrated, specialty orthopedic biomaterials company, announced the commercial availability of a complete line of bone grafting product solutions.

Read More

Topics: Orthopedics-OrthoBio

OrthoBio Market: SmartTRAK Predicts strong Growth Ahead

Posted by Sharon O'Reilly on 8/24/17 6:50 PM

Robust growth is predicted for the US OrthoBio market, driving revenues to over $4B by 2021E according to SmartTRAK projections.

  • Bone Replacement remains the largest segment of the US
  • Bone Replacement remains the largest segment of the US OrthoBio market, accounting for over 50% of total 2016 revenues, followed by Joint Fluid at nearly 30% based on 2016 SmartTRAK Financial Dashboard results.  Next in line are Knee Ligament Grafts, Cartilage, Soft Tissue and Meniscus replacement which account for the remainder...
Read More

Topics: Orthopedics-OrthoBio

Role of Injectable Therapies for Knee Osteoarthritis

Posted by Sharon O'Reilly on 5/2/17 1:22 AM

Injectable treatments will never turn a bad joint into a good one but may relieve pain for an undetermined period of time, concludes Elizaveta Kon, MD, in a conversation with BioMedGPS at the 2016 ICRS. Dr. Kon has performed extensive research comparing injectable technologies (e.g., PRP, HA, BMAC) and believes their primary role is in treating pain in pts who wish to avoid surgery. 

Read More

Topics: Orthopedics-OrthoBio

Another Showdown in the Hyaluronic Acid Market?

Posted by Sharon O'Reilly on 4/25/17 5:00 PM

AAOS Shifts Focus From Efficacy to Cost

The American Association of Orthopedic Surgeons (AAOS) has shifted their focus from efficacy to costs in their offensive against intra-articular hyaluronic acid therapy

Read More

Topics: Orthopedics-Total Joints, Orthopedics-OrthoBio

New Injectable Technologies For Knee Pain Highlighted at ICRS

Posted by Sharon O'Reilly on 12/5/16 10:00 AM

Two new injectable technologies that may potentially fill the gap in treatment options for patients with arthritic joints were highlighted in a session at the 2016 International Cartilage Repair Society (ICRS) in Sorrento, Italy.

Read More

Topics: Orthopedics-OrthoBio

Subscribe to News and Analysis Blog Weekly Emails

SmartTRAK is the leading source of competitive intelligence used by the top ten global orthopedic and wound care companies. 

Recent Posts